Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the ‘MOI-A’ study; a randomised, phase 2/pilot, dose-escalating trial

Introduction Osteogenesis imperfecta (OI) is the most common inherited cause of bone fragility (approximately 1 in 16 000). People with OI suffer bone fragility causing fractures, pain and deformity; sarcopenia causing fatigue and poor endurance; aortic root dilatation and hearing loss. No drug curr...

Descripción completa

Detalles Bibliográficos

Autores principales:	Judith Cohen, Chao Huang, Nick Bishop, Bronwen Williams, Laura Simms, Mahboobeh Haji Sadeghi, Amy Wilkinson, Sarah Sumpter, Keith Pugh, Charlotte Heath, Luca Sangiorgi, Francesca Gurioli, Maria Gnoli, Alice Moroni, Martina Piccinni Leopardi, Clara Del Coco
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMJ Publishing Group 2025-12-01
Colección:	BMJ Open
Acceso en línea:	https://bmjopen.bmj.com/content/15/12/e107243.full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!